News | June 14, 2021
Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
Aurobindo has one of the most enduring generics ecosystems among peers
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
The company plans to enter the EU markets in FY22
The company is working closely with its six manufacturing partners in India
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
The government has taken all the effective measures to make healthcare affordable
Subscribe To Our Newsletter & Stay Updated
